Supply Chain Archives
Managing the Cold Chain
07/07/2026
When Local Variation Becomes Global Risk in Phase III
By the time an advanced therapy program reaches Phase III, the supply chain is no longer being judged only by whether material can move from one point to another. It is being judged by whether that movement can be repeated across sites, regions, service providers, and regulatory environments in a way that produces a consistent and defensible record of execution.
Managing the Cold Chain
07/07/2026
“Regulatory Readiness is Built Early” and Other Lessons for CGT Developers
Advanced therapy developers are used to making hard decisions under pressure. In early development, the priority is often clear: reach the clinic, generate meaningful data, and keep the program moving. This was the central theme of the recent webinar, “Prevent Advanced Therapy Program Delays with Early Supply Chain Strategy.” The expert panel explored why early supply chain decisions deserve strategic attention long before a program reaches pivotal trials or filing preparation.
Managing the Cold Chain
04/21/2026
Accelerate Your Trials Without Losing Control With an End-to-End Supply Chain Model
As programs shift from Phase I to Phase II, the workload starts to overlap in new ways. Sample volumes increase as more sites operate in parallel, and activities that once occurred in sequence now run at the same time. The work itself is largely the same, but keeping it coordinated requires more time and attention.
Industry Insights
03/19/2026
ATC 2026 Keynote Recap: Building Global Readiness for Advanced Therapies
Alison Pritchard, VP of Business Development – EMEA at Cryoport Systems, delivered the Keynote Address at the Advanced Therapies Congress 2026, grounding the discussion in the accelerating pace of global expansion across the cell and gene therapy industry. Clinical trials now commonly stretch across regions, and manufacturing networks are distributed in ways that require constant coordination. These patterns have become the norm rather than the exception. As she described it, the operating environment for advanced therapies has already become global, and every program is expected to function within that reality much earlier than in the past.
Managing the Cold Chain
06/13/2025
Expanding Clinical Trials Internationally in the ATMP Space
Expanding an advanced therapy clinical trial internationally is an exciting milestone but can be daunting for researchers and biotech teams. International trials involve challenges like country-specific regulations, Qualified Person (QP) release, and complex logistics. Early planning for these issues can help avoid delays and ensure progress.
Patient Access and Awareness
05/19/2025
Clinical Trials Day: Supporting the Journey from Discovery to Delivery
Clinical trials represent hope, innovation, and the pursuit of better outcomes. They are the backbone of developing new diagnostics, vaccines, devices, and therapies. They help ensure safety, efficacy, and accessibility to the people who need them. That's why each year on May 20, the community comes together to celebrate Clinical Trials Day, honoring the anniversary of the first randomized clinical trial. At Cryoport Systems, we are honored to support our partners and clients in this journey.
Industry Insights
01/30/2025
Mapping the Future: Q&A with Mark Sawicki, Ph.D., on 2025 Trends in Cell and Gene Therapy
As the CGT industry enters a pivotal phase of commercial growth and therapy expansion, Cryoport Systems’ CEO, Mark Sawicki, Ph.D., shares his perspectives on where the market is headed.
Navigating Logistics
12/16/2024
